MOR vs. BHC, TGTX, MLTX, ACAD, CORT, MRUS, VERA, INDV, PTCT, and RNA
Should you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Bausch Health Companies (BHC), TG Therapeutics (TGTX), MoonLake Immunotherapeutics (MLTX), ACADIA Pharmaceuticals (ACAD), Corcept Therapeutics (CORT), Merus (MRUS), Vera Therapeutics (VERA), Indivior (INDV), PTC Therapeutics (PTCT), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical preparations" industry.
MorphoSys (NASDAQ:MOR) and Bausch Health Companies (NYSE:BHC) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking.
18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Companies shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 8.1% of Bausch Health Companies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Bausch Health Companies received 326 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 61.90% of users gave Bausch Health Companies an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
In the previous week, MorphoSys had 4 more articles in the media than Bausch Health Companies. MarketBeat recorded 9 mentions for MorphoSys and 5 mentions for Bausch Health Companies. MorphoSys' average media sentiment score of 0.57 beat Bausch Health Companies' score of 0.19 indicating that MorphoSys is being referred to more favorably in the media.
MorphoSys presently has a consensus target price of $11.78, indicating a potential downside of 38.00%. Bausch Health Companies has a consensus target price of $11.33, indicating a potential upside of 67.41%. Given Bausch Health Companies' higher possible upside, analysts clearly believe Bausch Health Companies is more favorable than MorphoSys.
Bausch Health Companies has a net margin of -5.07% compared to MorphoSys' net margin of -226.79%. MorphoSys' return on equity of -694.31% beat Bausch Health Companies' return on equity.
MorphoSys has higher earnings, but lower revenue than Bausch Health Companies. MorphoSys is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
MorphoSys has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.
Summary
Bausch Health Companies beats MorphoSys on 10 of the 18 factors compared between the two stocks.
Get MorphoSys News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MorphoSys Competitors List
Related Companies and Tools
